Mylan To Launch Generic Copaxone

Mylan Inc. announced yesterday that it plans to launch a generic version of Copaxone, Teva Pharmaceutical Industries Ltd. intravenous treatment for multiple sclerosis, in the second half of 2013. Mylan added that patent litigation and US Food and Drug Administration (FDA) approval of its drug are pending. In addition, the firm announced yesterday that it has entered into a facility agreement with a syndicate of banks to securitize up to $300 million of U.S. accounts receivable. The facility is committed and has a maturity of three years. View and share